Convexity Labs

CRC

Convexity Analyst · CRC
medium confidenceTactical · no named thesis
Generated Jun 21, 2026

Analyst Note: California Resources Corporation (CRC)

Date: 2026-06-13 Current Price: $55.30

1. Structural Readiness

  • Conservative Entry: Not yet triggered (requires a confirmed close above the consolidation ceiling).
  • Aggressive/Pre-Breakout Entry: Available for traders willing to accept the risk of a forming coil; entry is at current market price ($55.30).
  • Extension: Not applicable (price is within the consolidation range, not extended above the breakout level).
  • ATR Context: Current ATR is 3.8% (Productive). This sits within the historical "sweet spot" (4–6% is ideal, 3.8% is slightly below but indicates manageable volatility for sizing).

2. Thesis Layer

  • Thesis Classification: TACTICAL / SETUP-LED.
  • Macro Context: There is no named secular thesis attached to this specific setup as of 2026-06-13. The investment case is not driven by a broad, multi-year macro narrative (e.g., "The Great Green Transition" or "Global Energy Shortage") but is instead driven by the specific quality of the technical setup combined with the company's fundamental execution.
  • Judgment Criteria: Conviction must be derived strictly from the strength of the technical structure (the forming coil) and the verifiable business fundamentals (production growth, margin expansion, and capital efficiency) reported by management. Do not invent a macro thesis to justify the position.

3. Business Fundamentals

California Resources Corporation (CRC) is an independent energy company focused on the exploration, development, and production of crude oil, condensate, natural gas liquids (NGLs), and natural gas. Its operations are concentrated in major producing basins in California and Utah.

  • Production & Growth: As of the Q1 2026 earnings call (2026-05-06), management reported net production averaging 154,000 BOE per day, with oil comprising 81% of the mix. Management guidance targets full-year 2026 exit gross production of 175,000 BOE per day, representing approximately 1% entry-to-exit growth.
  • Capital Efficiency & Returns: Management has raised adjusted EBITDAX guidance by over 40%, outpacing the expected rise in Brent prices. At current strip prices, management expects a multiple of approximately 4.5x on invested capital (up from 3.8x previously) and an IRR approaching 70%.
  • Cash Flow & Shareholder Returns: The company expects full-year free cash flow (before working capital changes) to exceed $800 million. Management stated, "we expect to generate operating cash flow to return cash to shareholders through dividends."
  • Operational Expansion: Following the resumption of permitting in January 2026, CRC expanded its drilling program to include new well development in Kern County. The company plans to increase its rig program to seven rigs in the second half of 2026 (6 in California, 1 in Utah).
  • Strategic Initiatives (CCS): CRC completed the construction and commissioning of California's first commercial-scale carbon capture and storage (CCS) project at its Elk Hills cryogenic gas plant. Management expects final EPA termination notice "any day now." The company has submitted over 350 million metric tons of carbon storage capacity to the EPA.
  • Merger Integration: The company is integrating the Berry merger (announced Sept 2025), targeting annual run-rate synergies of $80 million to $90 million within twelve months of closing.

4. Archetype and Conviction

  • Archetype: Cyclical Recovery.
  • *Fit:* The name fits the Cyclical Recovery archetype due to the combination of a recovering production profile post-merger, significant margin expansion (EBITDAX up 40%), and a shift from pure growth to capital return (dividends) as cash flows turn robust. The "recovery" is evidenced by the ramp-up from 137 MBoe/d (Q1 2025) to 154 MBoe/d (Q1 2026) and the guidance to 175 MBoe/d.
  • Valuation Context: The financial spine indicates a Forward Consensus EPS of $6.37 for FY1 and $4.45 for FY2. At a current price of $55.30, the stock trades at approximately 8.7x FY1 consensus EPS.
  • Conviction Stack:
  • *Thesis Strength:* Moderate (Tactical, no macro tailwind).
  • *Evidence Quality:* High. Management has provided specific, quantified guidance on production, EBITDAX, IRR, and CCS permitting.
  • *Structural Quality:* High. The merger synergies and CCS project provide a unique operational moat compared to pure-play conventional producers.
  • *Rerating Potential:* Significant. The shift from a 3.8x to 4.5x multiple on invested capital suggests the market is beginning to re-rate the asset based on improved capital efficiency and CCS capabilities.

5. Invalidations, Strengths, and Gaps

  • What Would Strengthen: A confirmed breakout above the consolidation range. Fundamentally, the successful commissioning of the CCS project and the realization of the $80–$90M synergy targets would validate the "Cyclical Recovery" narrative.
  • Evidence Gaps:
  • Hedge Maturity: While 65% of 2026 production is hedged at $64.99, the specific impact of unhedged production on Q3/Q4 margins is not detailed beyond the general "strip prices" assumption.
  • Synergy Realization Timing: The $80–$90M synergy target is a 12-month run-rate; the exact timing of when these hit the P&L in 2026 is not broken down by quarter.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Management raised adjusted EBITDAX guidance by over 40% and targets 175,000 BOE/d exit production; IRR approaching 70% with a 4.5x multiple on invested capital; 65% of 2026 production hedged at $64.99 floor price. Key risks: Failure to secure EPA termination for CCS project; geopolitical volatility disrupting California operations; merger integration delays preventing synergy capture. Sizing hint: Position size should reflect the "forming" nature of the setup; allocate based on the 3.8% ATR volatility, treating the entry as a pre-breakout accumulation rather than a confirmed momentum play. Expected path: Management expects production to build momentum into 2027 with a 7-rig program in H2 2026; the market should re-rate the stock as the CCS project receives final regulatory approval and synergies are realized. Expected horizon: 6 to 12 months for the thesis to fully play out as the 2026 production targets are met and the CCS project is operational.

Loading chart...
Exhibit 1: CRC daily candlestick — no active setup overlay.

Source-backed evidence anchors and catalysts land once Convexity finishes coverage for CRC.

Core assumptions for this name haven't been articulated yet — they land alongside the rerating thesis.

Value picture unavailable — no financial spine on file for CRC.

Layer B fundamentals snapshot not yet available. Highlights land once Convexity finishes the classification.

Coverage: